Privosegtor (OCS-05)

About Oculis

Oculis is a global biopharmaceutical company on a mission to save sight and improve eye care through visionary innovation. Founded in 2014 and publicly listed on Nasdaq, the company has built a differentiated, late-stage pipeline targeting high-prevalence diseases with significant unmet needs, including diabetic macular edema (DME), dry eye disease (DED), and optic neuritis. Its strategy leverages proprietary technology platforms like OPTIREACH® to develop non-invasive topical treatments that challenge current invasive standards of care, positioning it as a potential leader in next-generation ophthalmology therapeutics.

About Oculis

Oculis is a global biopharmaceutical company on a mission to save sight and improve eye care through visionary innovation. Founded in 2014 and publicly listed on Nasdaq, the company has built a differentiated, late-stage pipeline targeting high-prevalence diseases with significant unmet needs, including diabetic macular edema (DME), dry eye disease (DED), and optic neuritis. Its strategy leverages proprietary technology platforms like OPTIREACH® to develop non-invasive topical treatments that challenge current invasive standards of care, positioning it as a potential leader in next-generation ophthalmology therapeutics.

Therapeutic Areas

Other Optic Neuritis Drugs